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ttp://dx.doi.org/10.1016/j.ajpath.2013.03.002Ectopic mineralization has been linked to several common clinical conditions with considerable morbidity
and mortality. The mineralization processes, both metastatic and dystrophic, affect the skin and vascular
connective tissues. There are several contributing metabolic and environmental factors that make
uncovering of the precise pathomechanisms of these acquired disorders exceedingly difﬁcult. Several
relatively rare heritable disorders share phenotypic manifestations similar to those in common conditions,
and, consequently, they serve as genetically controlled model systems to study the details of the
mineralization process in peripheral tissues. This overview will highlight diseases with mineral deposition
in the skin and vascular connective tissues, as exempliﬁed by familial tumoral calcinosis, pseudoxanthoma
elasticum, generalized arterial calciﬁcation of infancy, and arterial calciﬁcation due to CD73 deﬁciency.
These diseases, and their corresponding mouse models, provide insight into the pathomechanisms of soft
tissue mineralization and point to the existence of intricate mineralization/anti-mineralization networks
in these tissues. This information is critical for understanding the pathomechanistic details of different
mineralization disorders, and it has provided the perspective to develop pharmacological approaches to
counteract the consequences of ectopic mineralization. (Am J Pathol 2013, 183: 10e18; http://
dx.doi.org/10.1016/j.ajpath.2013.03.002)Supported by NIH/National Institute of Arthritis and Musculoskeletal
and Skin Diseases grants R01 AR28450 and R01 AR55225 (J.U.) and
a Dermatology Foundation Research Career Development Award (Q.L.).Ectopic Mineralization: A Global Pathological
Problem
Ectopic mineralization (ie, deposition of calcium/phosphate
complexes in connective tissues in aberrant locations) has
been linked to several clinical conditions, such as aging,
cancer, diabetes, and autoimmune diseases, major causes of
morbidity and mortality. For example, a recent study has
examined the risk of death associated with coronary artery
calciﬁcation in a cohort of 25,253 patients and found that
coronary artery calciﬁcation is an independent risk factor to
death, with the relative risk being up to 12.5-fold.1
Two major types of acquired ectopic mineralization
processes involving peripheral connective tissues have beenstigative Pathology.
.recognized. Metastatic calciﬁcation refers to calcium depo-
sition associated with elevated serum levels of phosphate and/
or calcium, as in chronic renal failure, whereas dystrophic
calciﬁcation is usually secondary to some form of insult to the
tissues, as seen in autoimmune diseases and cancer. Meta-
static calcinosis in the skin can be characterized clinically by
nodular deposits of calcium and phosphate, often in peri-
articular distribution, and they are reversible on correction of
the calcium and/or phosphate abnormalities.2 This can also be
seen in association with vascular calciﬁcation, as in calci-
phylaxis, which is associated with an approximately 70%
Heritable Mineralization Disordersmortality rate, and it commonly occurs in patients with
chronic renal failure, resulting in hyperphosphatemia.3
Dystrophic calciﬁcation occurs frequently in previously
damaged or diseased tissues. Localized skin involvement
occurs in many cutaneous inﬂammatory lesions, such as
acne, chronic ulcers, and granulomas, as well as in benign
and malignant neoplasms.2 Although calcinosis cutis can
present as small cutaneous deposits primarily on the ﬁngers
or elbows in patients with systemic sclerosis, it has also been
reported in patients with systemic lupus erythematosus and
dermatomyositis.4,5 In these conditions, dystrophic calciﬁ-
cation occurs without serum calcium/phosphate abnormali-
ties. Thus, ectopic mineralization represents the consequence
of several contributing metabolic and environmental factors,
making the uncovering of the precise basis of these disorders
in the populations at large exceedingly difﬁcult.
Heritable Diseases of Ectopic Mineralization
Skin Diseases with Mineral Deposition: Familial
Tumoral Calcinosis
Several Mendelian genetic disorders share phenotypic simi-
larities with the acquired forms of metastatic and dystrophic
calciﬁcation, and serve as genetically controlledmodel systems
to study various facets of pathological mineralization (Table 1).
Recent studies on these conditions, with accompanying animal
models, have allowed identiﬁcation of several genetic factors
that contribute to ectopic mineralization, providing evidence of
intricate mineralization/anti-mineralization networks in pe-
ripheral connective tissues (Figure 1).Table 1 Human Diseases with Ectopic Mineralization Phenotypes, Gen
Human disease Phenotypic features
PXE Mineralization in the skin, eyes, and
cardiovascular system
GACI Arterial calcification and joint and spine
ossiﬁcation
ACDC Vascular and joint calcification
NFTC Ulcerative mineralization lesions in skin
HFTC Mineralization masses in skin
Multiple vitamin
Kedependent
coagulation factor
deﬁciency
Vitamin Kedependent coagulation factor
deﬁciency and PXE-like skin changes
AI Arterial, pulmonary, and eye calcification
Keutel syndrome Arterial and cartilage calcification
Familial IBGC Vascular and pericapillary calcification in brai
FHH Cataracts, vibrissae, muscle, and vascular
calciﬁcation
ACDC, arterial calciﬁcation due to CD73 deﬁciency; AI, amelogenesis imperfecta;
familial tumoral calcinosis; IBGC, idiopathic basal ganglia calciﬁcation; NFTC, norm
The American Journal of Pathology - ajp.amjpathol.orgTwo forms of familial tumoral calcinosis affect primarily
skin and recapitulate features of acquired forms of meta-
static and dystrophic calciﬁcation. The hereditary counter-
part of acquired metastatic calcinosis is hyperphosphatemic
familial tumoral calcinosis (HFTC; Mendelian Inheritance
of Man 211900), an autosomal recessive condition char-
acterized by progressive deposition of calcium phosphate
crystals in periarticular spaces and soft connective tis-
sues.6,7 As in acquired cases of metastatic calciﬁcation,
HFTC is associated with marked hyperphosphatemia.
Mutations in one of three genes involved in the regulation
of phosphate excretion in the kidney may result in the
HFTC phenotype (Figure 1). First, loss-of-function muta-
tions in the ﬁbroblast growth factor 23 gene (FGF23) were
shown to cause HFTC.8 The protein encoded by FGF23
controls phosphate re-absorption in the kidney, and when
FGF23 is not functioning properly, phosphate excretion is
impaired and high levels of phosphate accumulate in the
circulation. Second, HFTC-causing mutations were identi-
ﬁed in GALNT3,9 a gene encoding UDP-N-acetyl-a-D-gal-
actosamine:polypeptide N-acetylgalactosaminyl-transferase
3, a glycosyltransferase that initiates mucinetype O-gly-
cosylation. Mechanistically, O-glycosylation of FGF23 by
this enzyme prevents proteolytic cleavage and inactivation
of FGF23, thus allowing its action under physiological
conditions.10,11 Finally, mutations in the KLOTHO gene,
encoding a coreceptor for FGF23, were found to be asso-
ciated with HFTC.12,13 Hence, the study of HFTC, a rare
genetic disorder, has led to the understanding of complex
biochemical processes of relevance to common acquired
diseases.es, and Corresponding Mutant Mouse Models
Gene, protein Mouse model
ABCC6, ATP-binding cassette
C subfamily, member 6
Abcc6/; KK/HlJ
ENPP1, nucleotide
pyrophosphatase
Enpp1/; ttw/ttw; asj
NT5E, CD73 Nt5e/
SAMD9, sterile a motif
domain containing 9
KL, klotho; GALNT3,
ppGaNTase-T3; FGF23,
ﬁbroblast growth factor 23
Klotho/; Galnt3/;
Fgf23/
GGCX, vitamin Kedependent
g-carboxylase
Ggcx/
FAM20A, family with sequence
similarity 20, member A
Fam20a/
MGP, matrix gla protein Mgp/
n SLC20A2, sodium-dependent
phosphate transporter 2
CASR, calcium-sensing receptor Casr/
GACI, generalized arterial calciﬁcation of infancy; HFTC, hyperphosphatemic
ophosphatemic familial tumoral calcinosis; PXE, pseudoxanthoma elasticum.
11
Figure 1 Genetic complexity of the mineralization/anti-mineralization network. Mutations in speciﬁc genes (also in Table 1) can result in deposition of
hydroxyapatite in several heritable ectopic mineralization disorders. The blue circles represent unidentiﬁed anti-mineralization factors transported by ABCC6
under physiological conditions from the intracellular milieu (IC) to the extracellular space (EC). HOPS, infantile hypophosphatasia.
Li and UittoThe second type of familial tumoral calcinosis, normo-
phosphatemic familial tumoral calcinosis (NFTC; Mende-
lian Inheritance of Man 610455), recapitulates features of
acquired dystrophic calcinosis and manifests with extensive
ectopic mineralization of the cutaneous tissues, associated
with preceding inﬂammatory manifestations mostly evident
in mucosal tissues. NFTC results from mutations in the
SAMD9 gene,14,15 which encodes an approximately 170-
kDa protein with unknown function. Gene expression
proﬁling of cell cultures derived from an aggressive ﬁbro-
matosis tumor with an adenomatosis polyposis coli mutation
has shown SAMD9 to be up-regulated on transfection with
the wild-type adenomatosis polyposis coli, although
SAMD9 expression was lower in aggressive ﬁbromatosis.16
Also, reduced levels of SAMD9 expression were noted in
20% of cases of breast cancer and 35% of cases of colon
cancer cell lines compared with normal tissue. Moreover,
cancer cells transfected with SAMD9 expression vector that
were injected into mice produced tumors of lower volume
compared with cancer cells transfected with an empty
vector. Thus, SAMD9 may play a role as a tumor-suppressor
gene, but the relevance of these observations to the miner-
alization phenotype remains unclear.16 Nevertheless, given
that SAMD9 deﬁciency in NFTC causes clinical manifesta-
tions of inﬂammation and because SAMD9 has been shown
to regulate apoptosis, it has been speculated that tumor
necrosis factor (TNF)-a, a cytokine that links inﬂammation
and apoptosis,17 might have a role in SAMD9 regulation.
Indeed, treatment of cells with TNF-a caused a sixfold
increase in SAMD9 transcription, and the increase in
SAMD9 expression was mediated through a p38 proin-
ﬂammatory and proapoptotic pathway.15 In addition, inhi-
bition of NF-kB, a factor that antagonizes the proapoptotic
response, caused a considerable increase in SAMD9
expression after treatment with TNF-a, thus suggesting that
SAMD9 functions, along the TNF-a signaling pathway, as
a possible repressor of this system.12Multisystem Mineralization Disorders: Pseudoxanthoma
Elasticum
A prototype of multisystem ectopic mineralization disorders
is pseudoxanthoma elasticum (PXE), characterized by
protean manifestations in the skin, the arterial blood vessels,
and the eyes.18 PXE is inherited in an autosomal recessive
manner and is caused by mutations in the ABCC6 gene
that encodes ABCC6, a transmembrane efﬂux transporter.
Interestingly, ABCC6 is expressed primarily in the liver, to
some extent in the kidneys and the intestine, but at low
levels, if at all, in tissues directly affected by mineralization
in PXE.19 Clinical observations on PXE, including late onset
of manifestations and slow, yet progressive, development of
the phenotype, coupled with studies using a knockout mouse
model, Abcc6/, as a platform (see later), have suggested
that PXE is a metabolic disorder with a primary molecular
defect in the liver.20 However, the precise pathomechanistic
details leading from ABCC6 mutations to mineralization in
peripheral tissues are unknown.21
The clinical manifestations of PXE are usually noted ﬁrst
in the skin, which manifests with small yellowish papules
on the predilection sites, such as the side of the neck and the
antecubital fossae.22 Although the cutaneous ﬁndings by
themselves are only of cosmetic concern, they signify the
potential for development of serious eye problems. Char-
acteristic eye lesions consist of angioid streaks that result
from breakage in the mineralized Bruch’s membrane behind
the retina. The angioid streaks are accompanied by capillary
breakage, bleeding to the eye, and neovascularization
resulting in progressive loss of visual acuity and central
blindness in most patients, if left untreated.23 The involve-
ment of the cardiovascular system reﬂects mineralization
of medium-sized arterial blood vessels and clinically
manifests with hypertension, intermittent claudication,
occasional bleeding from the intestinal arteries, and, rarely,
early myocardial infarcts and stroke.24ajp.amjpathol.org - The American Journal of Pathology
Heritable Mineralization DisordersPXE is a rare disease, with an estimated prevalence of
approximately 1:50,000, which implies that there are approx-
imately 7000 affected individuals in the United States and as
many as 150,000 in the world, assuming the same global
prevalence.25 Most patients have mutations in the ABCC6
gene, and approximately 600 distinct loss-of-function muta-
tions have been encountered, including recurrent p.R1141X
and g.del23-29, which account for up to approximately 45% of
all mutations.26 Recent clinical observations of the presence
of PXE-like cutaneous ﬁndings associated with unusual
phenotypes have revealed additional mutated genes. One of
them is vitamin Kedependent coagulation factor deﬁciency,
manifesting primarily with a bleeding disorder. In addition,
some of these families develop unusually loose and lax skin
with features of PXE.27,28 These patients harbor mutations
in the GGCX gene, which encodes vitamin Kedependent
g-glutamyl carboxylase.This enzymecatalyzesg-carboxylation
of glutamyl residues in several proteins, so-called Gla
proteins, which include several coagulation factors and
matrix Gla protein (MGP).29 MGP is present in peripheral
connective tissues serving as a powerful anti-mineralization
factor when in fully carboxylated form. Thus, as a result of
inactivating mutations in the GGCX gene, the MGP remains
uncarboxylated, thus allowing ectopic mineralization of the
peripheral connective tissues in the skin and arterial blood
vessels to ensue. Based on these observations, it has been
suggested that ectopic mineralization in PXE reﬂects deﬁ-
ciency of vitamin K, similarly leading to reduced levels of
fully carboxylated and, hence, active MGP.30 This hypoth-
esis has been tested by feeding Abcc6/ mice with high
doses of vitamin K1 or K2 or by intravenous injection of
vitamin Keglutathione conjugate.31e33 None of these treat-
ments resulted in amelioration or prevention of the ectopic
mineralization in this mouse model of PXE.
The role of vitamin K has also been examined by
feeding Abcc6/ mice with warfarin, an anticoagulant that
interferes with the vitamin K cycle by preventing the
reduction of oxidized vitamin K (epoxide) to its reduced
form (hydroquinone).34 Clinical use of warfarin has been
reported to be associated with mineralization of the arterial
blood vessels and cardiac valves.35 Feeding Abcc6/ mice
with a warfarin-containing diet resulted in massive accu-
mulation of mineral deposits in multiple tissues, well beyond
the levels noted in Abcc6/ mice fed a control diet. These
results suggested that further reduction in the g-glutamyl
carboxylation of MGP, caused by warfarin feeding, resulted
in severe ectopic mineralization. The clinical implication of
these experiments is that patients with PXE may be at risk of
worsening of their disease as a result of warfarin therapy.34
Heritable Disorders of Vascular Mineralization: GACI
and ACDC
Generalized arterial calciﬁcation of infancy (GACI), an
autosomal recessive disorder, has provided information on
the postulated mineralization/anti-mineralization networks inThe American Journal of Pathology - ajp.amjpathol.orgthe skin and vascular connective tissues.36 GACI and PXE
have been considered to be clinically two distinct conditions
in their classic forms: vascular mineralization in PXE is of
late onset, with accompanying skin and eye ﬁndings.
However, patients with GACI are often diagnosed as having
severe vascular mineralization prenatally or at birth, and
most of the latter patients die within the ﬁrst year of life.
GACI is caused by mutations in the ENPP1 gene, encoding
nucleotide pyrophosphatase phospodiesterase, an enzyme
that hydrolyzes ATP to generate AMP and pyrophosphate
(PPi), a powerful anti-mineralization factor
36,37 (Figure 1).
Recently, however, several families with characteristic
features of GACI have been shown to harbor mutations in
the ABCC6 gene, and surprisingly, many of these mutations
have been previously shown to cause PXE in unrelated
families.38,39 Of interest is a report on a family in which one
of the siblings died in early infancy, with clinical ﬁndings
consistent with GACI, whereas another sibling developed
late-onset manifestations characteristic of PXE, shown to be
associated with mutations in ABCC6.40 Attesting to the
clinical overlap of PXE and GACI is also a report on a
2-year-old patient with clinical ﬁndings of vascular calciﬁ-
cation diagnosed as having GACI and with associated
characteristic cutaneous ﬁndings of PXE.41 This patient was
shown to harbor a homozygous p.Y513C mutation in
ENPP1. Thus, mutations in the ENPP1 and ABCC6 genes
can present with phenotypic similarities between GACI and
PXE, attesting to the possibility of divergent mineralization
pathways due to underlying mutations in distinct genes.42
Another recently described clinical entity with vascular
involvement with similarities to PXE is arterial calciﬁcation
due to CD73 deﬁciency (ACDC) caused by mutations in
NT5E.43 The NT5E gene encodes CD73, an enzyme that is
linked to plasma membrane by glycosylphosphatidylinositol
and breaks down AMP to adenosine and inorganic phosphate
(Pi) (Figure 1). Although the mineralization affects primarily
arteries in the lower extremities, as in PXE, several histo-
logical differences have been indicated, suggesting different
pathological processes.44 As a consequence of CD73 deﬁ-
ciency, the activity of tissue non-speciﬁc alkaline phosphatase
is increased, accelerating the conversion of PPi to Pi, a pro-
calcifying factor (Figure 1). Furthermore, despite clinical
differences in the severity and localization of the vascular
calciﬁcation between GACI and ACDC deﬁciency, they both
reﬂect alterations in PPi/Pi metabolism and adenosine
signaling. How these observations relate to vascular miner-
alization in PXE remains to be explored. However, recent data
have speciﬁcally indicated that ABCC6 does not serve as an
efﬂux pump for adenosine under physiological conditions.45
Mouse Models of Heritable Ectopic
Mineralization Disorders
Understanding of the heritable ectopic mineralization disor-
ders has been advanced signiﬁcantly by examination of
animal models that often recapitulate the features of human13
Li and Uittodisease. In addition to providing information on the patho-
mechanistic pathways and modifying factors, many of these
mouse models have served as a platform to explore treatment
modalities for these often intractable disorders. An example
of a disease in which signiﬁcant progress has been made
toward understanding the underlying pathomechanisms
through study of mouse models is PXE. Speciﬁcally, the
Abcc6/ mice, developed by targeted ablation of the corre-
sponding mouse gene, recapitulate the genetic, histopatho-
logical, and ultrastructural features of the disease.46,47 An
early puzzling observation on PXE related to the fact that
the clinical manifestations, as a result of ectopic tissue
mineralization, affect primarily the skin, the vascular
connective tissues, and the eyes; however, the gene harboring
mutations in this disorder, ABCC6, is expressed predomi-
nantly in the liver, and at a low level, if at all, in clinically
affected tissues.19 This dilemma has been resolved by mouse
studies that have demonstrated that PXE is a primary meta-
bolic disorder, rather than a connective tissue disease, as
suggested earlier, and the primary pathological characteristics
reside in the liver, with subsequent downstream manifesta-
tions in peripheral connective tissues.20 This conclusion was
reached, in part, by parabiotic pairing of Abcc6/ mice with
their wild-type littermates.48 After having successfully
established a shared circulation, it was demonstrated that
knockout mice in Abcc6/; wild-type pairing did not
develop ectopic mineralization, in contrast to their counter-
parts in Abcc6/;Abcc6/ pairings. This and related ob-
servations suggested that the mineralization phenotype in
PXE is a result of lack of an anti-mineralization factor in the
circulation, which, under normal physiological conditions,
prevents calcium phosphate precipitation. It was then postu-
lated that such a factor, under normal physiological condi-
tions, is transported out of the liver to the circulation by
ABCC6, and in the absence of functional transporter activity
in PXE, such factor is missing in circulation, allowing ectopic
tissue mineralization to ensue.18
Several factors have been suggested to be the critical
molecule transported by ABCC6. The importance of iden-
tifying the missing anti-mineralization factor in circulation
of patients with PXE is emphasized by the fact that once the
identity of such a molecule has been disclosed, it can be
introduced directly to the circulation bypassing the liver,
and this approach would be expected to prevent further
mineralization. Based on clinical observations (previously
described), vitamin K or one of its derivatives has been
suggested to be the molecule whose absence in peripheral
tissues would lead to deﬁcient g-glutamyl carboxylation of
MGP and accumulation of inactive MGP.30 This suggestion
was supported by observations that MGP in the skin of
patients with PXE and in tissues of Abcc6/ mice is
undercarboxylated.49,50 Furthermore, it has been suggested
that the vitamin K levels in the serum of patients with PXE
are somewhat reduced.51 However, feeding of Abcc6/
mice with massive quantities of vitamin K did not prevent
or reverse the mineralization process.31e33 Furthermore,14subsequent liver perfusion experiments in Abcc6/ mice
and in Abcc6 vesicle transport systems failed to provide
evidence that vitamin K would be transported by ABCC6.52
In addition to Abcc6/ knockout mice, four naturally
occurring inbred mouse strains have been recently shown to
demonstrate connective tissue mineralization similar to
Abcc6/ mice.53,54 Further examination of these mice
revealed the presence of a single-nucleotide polymorphism in
Abcc6, which is predicted to result in substitution of arginine
by cysteine (p.R621C), but also to interfere with splicing of
the Abcc6 pre-mRNA. As a result, Abcc6 protein levels in the
liver were markedly reduced, indicating that these naturally
occurring strains of mice are allelic to the Abcc6/.
However, the four inbred strains harboring the same Abcc6
mutation displayed mineralizing phenotypes that were highly
variable, attesting to the notion that the genetic background
of mice, and presumably of patients with PXE, can modify
the mineralization phenotype. Thus, these mouse models
provide an opportunity to identify speciﬁc modiﬁer genes by
genome-wide association studies and quantitative trait locus
analyses. In fact, the development and the severity of the
mineralization phenotype in Abcc6/mice has already been
shown to be modulated by the Ggcx gene, and speciﬁcally,
the mineralization phenotype of Abcc6/ mice was accel-
erated when the mice were placed on a Ggcxþ/ background,
as compared with Abcc6/;Ggcxþ/þ mice.55 This observa-
tion is in support of digenic inheritance previously shown to
occur in a family with PXE-like cutaneous ﬁndings and with
a heterozygous ABCC6 mutation in one allele and a hetero-
zygous GGCX mutation in the other allele.56
In addition to Abcc6/ mice recapitulating PXE, several
mouse models for other heritable mineralization disorders
affecting the skin and/or the vascular connective tissues have
been described, including mice with mutant Enpp1 as
a model for GACI (Table 1). Several mouse models have
been shown to depict ectopic mineralization, some in the
dermal sheath of vibrissae and others in arterial blood vessels,
yet no human disease counterparts have been recognized as
of yet with mutations in the homologous genes (Table 2).
However, many of these conditions appear to provide clues to
the pathomechanisms of ectopic mineralization.
Mechanisms of Soft Tissue Mineralization
The mineral deposits in connective tissues in patients with
PXE and in Abcc6/ mice have been shown to consist of
calcium and phosphate that colocalize within the histologically
demonstrable lesions, as determined by energy-dispersive
X-ray.22,57 The ratio of calcium/phosphate progressively
increases with the maturation of the mineralized lesions,
reaching a value of approximately 2.0, comparable to the
endochondral bone.57 The progressive increase in mineraliza-
tion is also reﬂected by an increased mineral/matrix ratio, as
determined by Fourier-transform infrared imaging spectros-
copy, and determination of the mineral phases suggests
progressivematuration of themineral deposits fromamorphousajp.amjpathol.org - The American Journal of Pathology
Table 2 Mouse Models of Ectopic Mineralization without Corresponding Human Disease
Gene, protein Mouse model Phenotypic features
AHSG, a2-HS-glycoprotein/fetuin-A Ahsg/ Vascular calcification
ADIPOQ, adiponectin Apoe/ Aortic calcification
ANK, progressive ankylosis Ank/ Arterial and cartilage calcification
CA2, carbonic anhydrase 2 Car2/ Arterial calcification, osteopetrosis
OPN, osteopontin Opn/ No mineralization defect per se, but enhanced
vascular calciﬁcation in Mgp/ mice
OPG, osteoprotegerin Opg/ Osteoporosis, vascular calcification
SMAD6, SMAD family member 6 Madh6-mutant Aortic ossification
TIF1A, transcriptional intermediary factor 1aa Tif1a/ Calcification of arteries, vibrissae, and lungs
Heritable Mineralization Disorderscalcium phosphate to hydroxyapatite. This mineralization
process may be affected by the availability of the nucleation
sites in extracellular elastic structures and/or collagen ﬁbers
and by a tissue-speciﬁc microenvironment that favors miner-
alization, including the local concentrations of calcium and
phosphate and the presence of local and systemic anti-
mineralization factors. An explanation for the mineralization
may relate to thematrix-vesicle (MV)nucleatedmineralization,
and speciﬁcally, MVs have been shown to play an important
role in both skeletal and ectopicmineralization.58 It has, indeed,
been suggested that pathological mineralization of soft
connective tissues may have mechanisms similar to skeletal
calciﬁcation, and MVs may play a role in both mechanisms by
serving as a nucleation site. Vascular calciﬁcation has also been
suggested to follow the biomineralization pathway, in which
MV or MV-like particles in the tissue modulate the local
PO4
3-/PPi ratio. Because PPi is a powerful inhibitor of mineral
formation, changing the Pi/PPi ratio could either trigger or
inhibit mineral formation, depending on the precise balance of
these ions. Irrespective of the precise mechanisms, however,
understandingof theoverallmineralizationprocesses andof the
composition of the ﬁnal deposits can provide information
relevant to potential inhibition of the formation of early
precursors and their transformation into crystal and mineral
phases.
Anti-Mineralization Networks
Several factors, either systemic or local, can antagonize the
aberrant mineralization of connective tissues, and several
studies have noted direct association of these factors, such as
fetuin-A, MGP, Ank, and alkaline phosphatase activity, with
mineralization processes.59 Fetuin-A, also known as a2-
Heremans-Schmid glycoprotein, is a systemic inhibitor of
mineralization. The critical role of fetuin-A as an anti-
mineralization factor is attested by development of severe
calciﬁcation in various organs of Ahsg/mice, in which the
gene encoding fetuin-A has been ablated.60 This minerali-
zation phenotype is not associated with changes in calcium
and phosphate homeostasis, but results from decreased
inhibitory activity of fetuin-A in serum of these animals.
Ultrastructural and biophysical data have demonstrated
that fetuin-A inhibits mineralization by incorporating into
soluble colloidal spheres with calcium and phosphate. TheseThe American Journal of Pathology - ajp.amjpathol.orgsoluble calciprotein particles ordinarily become progressively
more crystalline and insoluble in a time- and temperature-
dependent manner, but the presence of fetuin-A facilitates
solubilization of these particles, thus providing a mechanistic
framework to remove insoluble calcium precipitates and
transport them away from the site of mineralization.61
Another protein intimately linked to the regulation of tissue
mineralization is MGP, which is expressed abundantly in
vascular smooth muscle cells. Mice lacking MGP die within
a fewmonths of age because of mineralization of elastic ﬁbers
and rupture of elastic arteries, such as aorta.62 The presence of
MGP has been demonstrated in association with elastic
laminae in human arterial blood vessels, but such colocali-
zation is lost in areas of vascular calciﬁcation, and MGP is
found primarily in the extracellular matrix at the borders of
vascularmineralization. These data support the notion of close
association between MGP and the mineralization process and
the role of the biologically inactive, undercarboxylated form
of MGP in vascular calciﬁcation in vitamin K deﬁciency.63
Collectively, the pathological processes leading to con-
nective tissue mineralization in heritable disorders have
both systemic and local regulatory factors, and the precise
balance of promineralization and anti-mineralization factors,
when superimposed on the individual’s genetic background,
determines the phenotypic features and severity of ectopic
mineralization.
Pharmacological Perspective
There is no effective treatment for the systemic manifesta-
tions of ectopic mineralization disorders, such as PXE and
GACI. In case of PXE, intravitreous injection of vascular
endothelial cell growth factor antagonists prevents the neo-
vascularization in the eyes, and signiﬁcant improvement in
the visual acuity has been reported.23 However, the systemic
mineralization in PXE progresses with advancing age, and
the manifestations in the skin and the cardiovascular system
become more evident. In case of GACI, some success has
been reported by use of bisphosphonates, nonhydrolyzable
pyrophosphate analogues, with carbon substituting for
oxygen and two R groups that substitute for phosphate.64
These drugs have been used to target bone, where they
have anti-osteoclastic biological activity, in addition to
physical inhibition of the formation of hydroxyapatite,15
Li and Uittomimicking that of PPi. The bisphosphonates were originally
introduced as agents to treat Paget’s disease and osteoporosis,
disorders in which the osteoclasts are overly active. The ﬁrst
bisphosphonates to be introduced were weak anti-osteoclastic
agents requiring their use in high doses, which resulted in an
untoward adverse effect of osteomalacia, due to inhibition of
bone mineralization. However, newer and more potent anti-
osteoclast agents are used in lower doses, which reduce the
inhibitory effects on bone mineralization. In GACI or other
mineralization disorders, such as PXE, one does primarily
want to inhibit mineralization with minimal effects on osteo-
clasts. Consequently, careful selection of the bisphosphonates
for treatment of these disorders is required to maximize the
inhibition of mineralization and minimize the adverse effects
due to anti-osteoclastic activity.
Another approach to prevent systemic mineralization (ie,
supplementation of the dietwithmagnesium)has been recently
suggested to be potentially useful for treatment of patients with
PXE. Early animal experiments feeding Abcc6/ mice with
a diet fortiﬁed with magnesium up to levels that are ﬁve times
higher than in the standard rodent diet completely prevented
the connective tissue mineralization in these mice.65 Con-
versely, reduction of the magnesium concentration to
approximately 20% of that in control diet accelerated the
mineralization process in the Abcc6/ mice.55,66 The mech-
anisms of inhibition of mineralization in this mouse model
relate to formation of mineral complexes in which magnesium
replaces calcium, and the excess calcium is excreted in the
urine. Because magnesium phosphate complexes are more
soluble under physiological conditions than those consisting of
calcium phosphate, less mineralization occurs, potentially
providing a useful treatment modality for patients with ectopic
mineralization disorders. Based on these preclinical murine
studies, a double-blinded clinical trial of patients with an
experimental diet in which the magnesium content has been
approximately doubled is under way (http://clinicaltrials.gov/
show/NCT01525875, last veriﬁed November 2012). Because
the progression of clinical signs and symptoms of PXE is
slowly progressing and variable, and no biomarker is available
to gauge the progress of mineralization, this study will be
extended to 2 years to accurately document the efﬁcacy of
magnesium as an anti-mineralization agent. Because the
mouse studies indicated that magnesium is effective in pre-
venting the mineralization process, but not in reversing the
existing mineral deposits, such dietary manipulation, if shown
by the clinical trials to be effective, should be instituted as soon
as the diagnosis has been established.Acknowledgments
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